Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

Telisotuzumab vedotin (formerly ABBV‐399) is an antibody‐drug conjugate targeting c‐Met–overexpressing tumor cells, irrespective of MET gene amplification status. Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan. This phase 1 open‐label stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Kenmotsu, Hirotsugu, Yamamoto, Noboru, Shimizu, Toshio, Yonemori, Kan, Ocampo, Christopher, Parikh, Apurvasena, Okubo, Sumiko, Fukasawa, Kazuteru, Murakami, Haruyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982615/
https://www.ncbi.nlm.nih.gov/pubmed/33675179
http://dx.doi.org/10.1002/cam4.3815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982615/
https://www.ncbi.nlm.nih.gov/pubmed/33675179
http://dx.doi.org/10.1002/cam4.3815

Ejemplares similares